MARKET

GKOS

GKOS

Glaukos Corp
NYSE

Real-time Quotes | Nasdaq Last Sale

47.66
+2.24
+4.93%
After Hours: 47.66 0 0.00% 16:03 07/01 EDT
OPEN
45.65
PREV CLOSE
45.42
HIGH
47.74
LOW
45.11
VOLUME
278.15K
TURNOVER
0
52 WEEK HIGH
86.35
52 WEEK LOW
33.33
MARKET CAP
2.26B
P/E (TTM)
-78.2980
1D
5D
1M
3M
1Y
5Y
Glaukos Announces Participation in the William Blair Growth Stock Conference
SAN CLEMENTE, Calfi., June 02, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its ma...
Business Wire · 06/02 11:00
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
SAN CLEMENTE, Calif., May 20, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its man...
Business Wire · 05/20 11:00
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Zacks · 05/10 15:04
--Stifel Nicolaus Adjusts Price Target for Glaukos to $40 From $55, Maintains Hold Rating
MT Newswires · 05/10 14:12
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:45
BRIEF-Glaukos Corporation Announces First Quarter 2022 Financial Results
reuters.com · 05/04 21:23
Glaukos Q1 Adj. EPS $(0.38) Beats $(0.50) Estimate, Sales $67.70M Beat $60.85M Estimate
Glaukos (NYSE:GKOS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.50) by 24 percent. This is a 80.95 percent decrease over losses of $(0.21) per share from the same
Benzinga · 05/04 20:18
Glaukos Non-GAAP EPS of -$0.38 beats by $0.13, revenue of $67.7M beats by $6.85M
Glaukos press release (NYSE:GKOS): Q1 Non-GAAP EPS of -$0.38 beats by $0.13. Revenue of $67.7M (-0.4% Y/Y) beats by $6.85M.
Seekingalpha · 05/04 20:16
More
No Data
Learn about the latest financial forecast of GKOS. Analyze the recent business situations of Glaukos Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.00%Strong Buy
0.00%Buy
60.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average GKOS stock price target is 54.29 with a high estimate of 70.00 and a low estimate of 40.00.
High70.00
Average54.29
Low40.00
Current 47.66
EPS
Actual
Estimate
-0.41-0.31-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 307
Institutional Holdings: 57.12M
% Owned: 120.67%
Shares Outstanding: 47.33M
TypeInstitutionsShares
Increased
73
3.00M
New
29
275.04K
Decreased
73
2.95M
Sold Out
24
648.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.13%
Healthcare Equipment & Supplies
+1.92%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Burns
President/Chief Operating Officer
Joseph Gilliam
Chief Financial Officer/Senior Vice President
Alex Thurman
Other
Tomas Navratil
Lead Director/Independent Director
Mark Foley
Independent Director
David Hoffmeister
Independent Director
Gilbert Kliman
Independent Director
Marc Stapley
Independent Director
Denice Torres
Independent Director
Aimee Weisner
Independent Director
Leana Wen
No Data
No Data
About GKOS
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. It is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants that are designed to elute pharmaceuticals.

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.